FDA Warns of Serious Risks from Hair Loss Sprays

The FDA warned that unapproved topical finasteride sprays cause serious side effects like erectile dysfunction. Thirty-two cases, including one veteran’s harm, were reported.
Companies like Hims claim to disclose risks, but critics say profits trump safety. The FDA’s alert highlights dangers in the growing telehealth market.
Some support telehealth’s convenience, while others demand stricter drug oversight. The warning may lead to new rules for online prescriptions.

Full Story

The FDA issued a warning about unapproved topical finasteride products, like those sold by Hims and Keeps, citing risks including erectile dysfunction and suicidal thoughts. The agency reported 32 cases of severe side effects, including one veteran’s significant physical harm. Telehealth firms claim they disclose risks, but critics question their priorities.

Finasteride is a drug traditionally used orally to treat hair loss and prostate issues. Topical versions, applied as sprays, lack FDA approval due to insufficient safety data.

See how news sources on all sides are covering this story.

Left 38% | Right 25% | Center 31% | Unrated 6%

The Context

The FDA’s alert follows reports of serious side effects, including anxiety and brain fog. One ex-Army sergeant reportedly suffered extreme physical changes from the product.

Telehealth companies like Hims have grown rapidly, offering convenient access to prescriptions. Critics argue their focus on sales overshadows patient safety concerns.

The 32 reported cases highlight the risks of unapproved drugs in a booming market. The FDA urges consumers to check product approvals before use.

Some defend telehealth firms, noting they provide accessible care and risk disclosures. Others believe lax oversight allows dangerous products to reach consumers.

Public opinion splits on balancing innovation with regulation in healthcare. Stricter rules could protect users but limit access to new treatments.

The warning underscores the FDA’s role in monitoring drug safety amid rising telehealth use. It may prompt tighter regulations for online prescriptions.

Coverage Details
Total News Sources32
Left12
Right8
Center10
Unrated2
Bias Distribution38% Left
Relevancy

Last Updated

Bias Distribution

FDA’s warning protects consumers, highlighting need for stricter cosmetic product regulations.

FDA overreaches on hair loss sprays, stifling innovation with excessive caution.

FDA’s alert on hair loss sprays balances safety with ongoing product scrutiny.

FDA’s hair loss spray warning raises safety concerns.